Urology
Volume 68, Issue 6 , Pages 1178-1182 , December 2006

Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy

  • Kazuhiro Araki

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • Corresponding Author InformationReprint requests: Kazuhiro Araki, M.D., Department of Urology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba 260-8670 Japan.
    • ,
  • Tatsuo Igarashi

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • Research Center for Frontier Medical Engineering, Chiba University, Chiba, Japan
    • ,
  • Toyofusa Tobe

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • ,
  • Kenichi Mizoguchi

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • ,
  • Hiroyoshi Suzuki

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • ,
  • Yuzo Furuya

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • ,
  • Tomohiko Ichikawa

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    • ,
  • Hiro-Omi Nakatsu

      Affiliations

    • Department of Urology, Asahi General Hospital, Chiba, Japan
    • ,
  • Haruo Ito

      Affiliations

    • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan

Received 16 October 2005 ,Accepted 14 August 2006.

References 

  1. McNichols DW, Segura JW, DeWeerd JH. Renal cell carcinoma: long-term survival and late recurrence. J Urol. 1981;126:17–23
  2. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988;48:7310–7313
  3. Igarashi T, Tobe T, Kuramochi H, et al. Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2001;31:13–17
  4. Ueda T. Serum immunosuppressive acidic protein in renal cell carcinoma. Urol Res. 1986;14:101–103
  5. Igarashi T, Murakami S, Tanaka M, et al. Preoperative grading of renal cell carcinoma by plasma immunosuppressive acidic protein level and tumor diameter using discriminant analysis. Jpn J Urol. 1993;84:884–889
  6. Igarashi T, Murakami S, Isaka S, et al. Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma. Eur Urol. 1991;19:332–335
  7. Pummer K, Purstner P, Auner HL, et al. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. Br J Urol. 1994;73:612–614
  8. Mani S, Todd MB, Katz K, et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35–40
  9. Citterio G, Bertuzzi A, Tresoldi M, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol. 1997;31:286–291
  10. Lissoni P, Barni S, Ardizzoia A, et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology. 1994;51:59–62
  11. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, et al. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology. 1996;48:373–378
  12. Aaltomaa S, Lipponen P, Ala-Opas M, et al. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol. 1997;31:350–355
  13. Pich A, Chiusa L, Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron. 2000;31:133–141
  14. Shibata Y, Tamura K, Ishida N. Cultured human monocytes, granulocytes and a monoblastoid cell line (THP-1) synthesize and secrete immunosuppressive acidic protein (a type of alpha 1-acid glycoprotein). Microbiol Immunol. 1984;28:99–111
  15. Shibata Y, Tamura K, Ishida N. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res. 1983;43:2889–2896
  16. Igarashi T, Murakami S, Takahashi H, et al. Mechanism of elevation of plasma immunosuppressive acidic protein level in renal cell carcinoma. JPN J Tumor Marker Res. 1995;10:25–27
  17. Kurzrock R, Estrov Z, Ku S, et al. Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med. 1998;131:261–268
  18. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607–610
  19. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52–55
  20. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348–353
  21. Miyata Y, Koga S, Nishikido M, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology. 2001;58:161–164

PII: S0090-4295(06)02066-8

doi: 10.1016/j.urology.2006.08.1071

Urology
Volume 68, Issue 6 , Pages 1178-1182 , December 2006

Article Tools

* Image Usage & Resolution